Citations

Clear

106 citation(s) found for "Subramaniam, B".

Virtual reality for cardiology case-based learning
Riener, Kurtis, Subramaniam, Anna, Bird, Jared, Tan, Nicholas, Simard, Trevor, Riener, Kurtis W. , Miller, Jack R. , Al‐Abcha, Abdullah , Simard, Trevor

Mayo Clinic

Frontiers in Virtual Reality | June 12, 2026 | Volume: 7 | Issue: No issue available | Pages: No page available

10.3389/frvir.2026.1841021 Get It

The ever-changing landscape of cardiology necessitates continuous education of healthcare providers. Case-based learning (CBL) provides an inquiry-based form of learning where learners apply knowledge to realistic clinical scenarios under instructor guidance. However, current case-based learning curricula are limited to representing 3-dimensional content in 2-dimensions with distinct modalities utilized for various data sources. Virtual reality (VR) shows promise for CBL given it provides an immersive and interactive 3-dimensional medium in which multi-source content can be incorporated into a unified learning experience, potentially translating to improved learning efficiency and lower cognitive load. With VR case-based learning, learners can view medical imaging in 3-dimensions or seamlessly interact with various 2-dimensional images within one unified medium. Further, additional content including simulated patients or procedures can be incorporated with a higher level of fidelity. Herein, we summarize the current literature exploring VR-CBL, demonstrate a proof-of-concept VR application, and review the implications for cardiology education. The proof-of-concept exemplifies many of the key advantages unique to VR-CBL, such as medical imaging rendered in 3-dimensions, integration of multiple imaging sources, and novel interaction methodologies. Given the importance and rapid evolution of ongoing medical education, VR-CBL, with its immersive and engaging nature, appears to be a promising form of instruction that may serve a larger role in continuing medical education initiatives.
NRG-HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.
Lai, Stephen Yenzen, Attwood, Kristopher, Chang, Steven S., Khan, Saad A., Dunlap, Neal, Beadle, Beth M. , Yu, Jian Q. , Lowe, Val J., Truong, Minh Tam, Kovalchuk, Nataliya , Rong, Yi, Kappadath, S Cheenu, Bell, Diana, Liu, Cheng Z., Abazeed, Mohamed E. , Le, Quynh-Thu Xuan, Yom, Sue S., Le, Quynh‐Thu , Khan, Saad A. , Le, Quynh-Thu , Dunlap, Neal , Attwood, Kristopher M. , Subramaniam, Rathan M. , Lowe, Val J. , Truong, Minh Tam, Kappadath, Srinivas Cheenu , Bell, Diana, Yom, Sue S

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps6138 Get It

TPS6138 Background: Patients with early-stage oral cavity cancer (OCC; T1-2N0M0; AJCC 8th edition) have a 20-30% risk of occult nodal metastases despite clinical and radiographic evaluations. Standard-of-care treatment for most patients includes elective neck dissection (END), which requires surgical removal of the regional cervical lymph nodes, even though 70-80% of these necks are disease-free. Sentinel lymph node biopsy (SLN Bx), a less invasive procedure, could assess the first echelon lymph nodes as an alternative to END, potentially reducing morbidity and costs. A pivotal clinical trial comparing SLN Bx to END (NCT#04333537) is underway to inform efforts to establish optimal disease management for early-stage OCC. Methods: To assess the efficacy of SLN Bx in this population, we activated an international, multi-institutional, prospective phase II/III trial in July 2020, randomizing patients to two surgical arms: SLN Bx and END. A node-negative 18 F-FDG PET/CT imaging biomarker study with centralized read was required before randomization. OCC patients with a positive PET/CT remained in a registry to compare imaging findings with final neck pathology. Given the current evidence on morbidity for SLN Bx versus END, the phase II was designed to determine whether the change in patient-reported neck and shoulder function and related quality of life (QOL) from baseline to 6 months after surgery, using the Neck Dissection Impairment Index (NDII), showed a signal of superiority of SLN Bx compared to END (minimum important difference ³ 7.5; one-sided a = 0.10; 90% power). As of December 2024, 261 patients had been randomized and 203 were analyzed for the “Go/No-Go” decision to move forward into phase III. The phase III portion is a non-inferiority (NI) trial with disease-free survival (DFS) as the primary endpoint (NI margin hazard ratio 1.34 based on a 5% absolute difference in 2-year DFS; one-sided a = 0.05; 80% power, and two interim looks). The change in NDII from baseline to 6 months after surgery is a hierarchical co-primary endpoint for phase III. Phase III opened in October 2025 upon receiving a “Go” signal from phase II. Target accrual for phase III is 686 node-negative PET/CT patients, including those randomized in phase II (425 additional patients). In addition to sites requiring radiotherapy and imaging credentialing, quality assurance will include central pathology review of all negative SLN Bx cases and surgeon credentialing through an education course with SLN Bx and END case review by the surgical co-chairs. A surgical quality assurance working group will review all trial SLN Bx and END procedures. As of 01/12/26, 351 patients have been screened, and 273 of the planned 686 have been randomized. Clinical trial information: NCT#04333537 .
A56-23 Effect of Sex on the Relationship Between Perioperative Risk Factors and Postoperative Pulmonary Complications After Non-Cardiothoracic Surgery in Asa III Patients
Mirza, S, Fernandez-Bustamante, A, Frendl, G, Juraj, S, Subramaniam, B, Martinez-Ruiz, R, Lee, J W, Bartels, K, Giquel, J, Schultz, M, Vermeulen, T D, Leu, C -S, Melo, M F Vidal, Frendl, György , Fernandez-Bustamante, Ana , Subramaniam, Bala , Martinez-Ruiz, Ricardo, Bartels, Karsten , Giquel, Jadelis, Vermeulen, Tom D

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4640 Get It

Abstract Rationale Postoperative pulmonary complications (PPCs) importantly contribute to postoperative morbidity and mortality, particularly for American Society of Anesthesiologists (ASA) physical status III patients. It remains unclear whether risk factors for PPCs depend on sex. We hypothesised that sex modifies the relationship between perioperative risk factors and PPCs in ASA III patients undergoing noncardiothoracic surgery with general anesthesia. Methods We performed a secondary analysis of prospective data from 1,202 ASA III patients undergoing non-cardiothoracic surgery. Data consisted of preoperative demographics, comorbidities, intraoperative physiology, medications, and procedure information. The primary outcome was a composite of PPCs by postoperative day 7. Mixed-effects linear models incorporated sex as main effect and interaction with covariates. Results Age, chronic obstructive pulmonary disease, upper abdominal surgery, surgical duration, and emergency surgery significantly increased the odds of ≥ 1 PPC by postoperative day 7. Male patients presented a higher rate of ≥ 3 PPCs, and mechanical ventilation was less protective in female patients. Yet, sex did not significantly modify the relationship between perioperative factors and the primary outcome (no p<0.05 for the interaction effect with sex). In the secondary analysis, gastroesophageal reflux disease affected atelectasis more strongly in male than female patients (relative odds-ratios for female versus male =0.27; 95% CI 0.13 to 0.57). Conclusions In ASA III patients undergoing non-cardiothoracic surgery with general anesthesia, perioperative factors are predominantly not significantly modified by sex in their relationship to PPCs. GERD’s association with atelectasis in male patients could be explored in future prospective studies as a target for reducing pulmonary complications. This abstract is funded by: NHLBI - UH3 HL140177
Family History and Solar Insolation in Bipolar I Disorder
Bauer, M., Glenn, Tasha , Achtyes, E. D., Alda, M., Ağaoğlu, Esen , Altınbaş, Kürşat , Andreassen, O. A., Angelopoulos, E., Ardau, R., Aydin, Mehmet Zeki , Ayhan, Y., Baethge, Christopher , Bauer, Rita, Baune, B. T., Balaban, Ceylan, Becerra‐Palars, Claudia, Behere, A. P., Belete, Habte , Belete, Tilahun, Belizario, G. Okawa, Bellivier, F., Belmaker, R. H., Benedetti, F., Berk, M., Bersudsky, Y., Bicakci, Ş., Birabwa‐Oketcho, Harriet , Bjella, T. D., Brady, Conan , Cabrera, Jorge , Cappucciati, Marco , Castro, A. M. Paredes, Chen, W., Cheung, E. Y. W., Chiesa, S., Chanopoulou, Margarita, Cuomo, A., Dodd, S., Etain, B., Fagiolini, A., Fellendorf, F. T., Ferensztajn‐Rochowiak, Ewa , Fiedorowicz, J. G., Fountoulakis, K. N., Frye, M. A., Geoffroy, P. A., Gitlin, M. J., Gottlieb, J. F., Grof, Paul , Haarman, B.C.M., Harima, Hirohiko, Hasse‐Sousa, M., Henry, C., Hoffding, L., Houenou, J., Imbesi, M., Isometsä, E. T., Janno, Sven , Johnsen, S., Karakatsoulis, G. N., Kardell, Mathias, Kessing, L. V., Kim, S. J., Kot, T. L., Koval, M., Lafer, B., Landén, M., Larsen, E. R., Licht, R. W., Ludwig, V. M., Mackenzie, Alan, Madsen, H. Østergaard, Madsen, S. Alberte Kongstad A., Mahadevan, J., Mahardika, Agustine , Mahfoudh, K. Ben, Manchia, M., Marsh, W., Martiny, Klaus , Mashima, Y., McLoughlin, D. M., Meesters, A. N. R., Meesters, Ybe , Melle, I., Meza‐Urzúa, F., Michaelis, Elisabeth, Mok, Y. Ming, Monteith, Scott , Moorthy, Muthukumaran, Morken, G., Mosca, Enrica, Mozzhegorov, A. A., Munoz, R., Mythri, S. V., Nadella, R. K., Nakanotani, Takako, Nielsen, R. Ernst, O'Donovan, C., Omrani, Adel, Osher, Yamima , Pantovic‐Stefanovic, M., Pariwatcharakul, Pornjira, Petite, Joanne, Pilhatsch, M., Ruiz, Y. Pica, Pinna, M., Pompili, M., Porter, R., Quiroz, Danilo , Rabelo‐da‐Ponte, F. Diego, Ramesar, Raj , Rasgon, NL, Redahan, Maria, Reddy, M. S., Reif, A., Reininghaus, E. Z., Richards, J. Gringer, Rybakowski, J. K., Sathyaputri, Leela, Scippa, A. M., Simhandl, Christian , Smith, D., Smith, J., Stackhouse, P. W., Stein, D. J., Stilwell, Kellen, Su, K.‐P., Sulaiman, A. Hatim, Suominen, Kirsi, Tanra, A. J., Tatebayashi, Yoshitaka , Teh, W. Lin, Tondo, L., Torrent, C., Tuinstra, Daniel, Uchida, Takahito, Vaaler, A. E., Vieta, E., Viswanath, B., Volf, C., Yang, K‐J, Yalcinkaya, O. Kaan, Young, A. H., Zgueb, Yosra , Whybrow, P. C., Houenou, Josselin , Isometsä, Erkki , Licht, Rasmus Wentzer , Manchia, Mirko , Nielsen, René Ernst , Stein, Dan J. , Kessing, Lars Vedel , Young, Allan H. , Achtyes, Eric D. , Belete, T , Berk, Michael , Crowe, M , Fagiolini, Andrea , Frye, Mark , Grof, P , Kessing, L V , Kim, S J , Manchia, Mirko , McLoughlin, D M , Nadella, R K , Ouali, U , Pariwatcharakul, P , Pompili, M , Porter, R , Ritter, P , Rybakowski, Janusz K , Stein, Dan J , Strejilevich, S , Subramaniam, M , Vaaler, A E , Vieta, E , Yoldi-Negrete, M , Young, Allan H , Bauer, M., Alda, Martin , Altınbaş, Kürşat , Andreassen, Ole A. , Angelopoulos, Elias, Ardau, Raffaella , Aydin, M., Ayhan, Yavuz , Behere, Aniruddh Prakash, Belizário, Gabriel Okawa , Bellivier, Frank , Belmaker, Robert H. , Benedetti, Francesco , Berk, Michael , Bıçakcı, Şule , Bjella, Thomas , Castro, Angela Marianne Paredes , Cuomo, Alessandro, Dallaspezia, Sara , Desai, Pratikkumar Vrajeshbhai , Dodd, Seetal , Étain, Bruno , Fagiolini, Andrea , Fellendorf, F.T., Fiedorowicz, Jess G. , Fountoulakis, Konstantinos Ν. , Frye, Mark A. , Geoffroy, Pierre A. , Gitlin, Michael , González‐Pinto, Ana , Haarman, Bartholomeus C. M. , Hasse-Sousa, Mathias , Henry, Chantal , Høffding, Lone, Imbesi, Massimiliano, Ivković, Maja , Johnsen, Søren Paaske , Kapczinski, Flávio , Karakatsoulis, Grigorios N. , König, Barbara , Kunz, Maurício , Lafer, Beny , Landén, Mikael , Ludwig, Vera Miriam , López‐Jaramillo, Carlos , MacKenzie, A., Madsen, Helle Østergaard , Mahfoudh, K., Marsh, W., Martínez‐Cengotitabengoa, Mónica , Martini, Julia , Mashima, Yuki , Meesters, Alie N.R., Melle, Ingrid , Meza-Urzúa, Fátima, Mikoláš, Pavol , Mok, Yee Ming , Morken, Gunnar , Mozzhegorov, Anton A., Mythri, SV, C, O'Donovan, Ouali, Uta , Stefanovic, M. Pantovic, Pfennig, Andrea , Ruiz, Yolanda Pica, Pinna, Marco , Rabelo-Da-Ponte, F.D., Rasgon, Natalie , Ratta‐apha, Woraphat , Redahan, Maria, Reif, A., Reininghaus, EZ, Ritter, Philipp , Strejilevich, Sergio , Suominen, Kirsi, Teh, Wen Lin , Torrent, C., Vieta, Eduard , Viswanath, Biju , Yoldi‐Negrete, María , Young, A.H., Whybrow, Peter C.

Mayo Clinic

Acta Psychiatrica Scandinavica | March 8, 2026 | Volume: 153 | Issue: 4 | Pages: 270-278

10.1111/acps.70075 | PMID 41734899 Get It

ABSTRACT Background Sunlight has profound impacts on physical and mental health, beyond vision, including effects on circadian rhythms, alertness, mood, and sleep. A family history of any mood disorders is strongly associated with psychiatric disorders including bipolar disorder. The purpose of this study was to evaluate the association between a family history of any mood disorder in patients with bipolar I disorder and solar insolation at varied international onset locations. Methods Data for this analysis were available from 5842 patients with a diagnosis of bipolar I disorder obtained at 83 collection sites in both hemispheres. This included 4752 patients from 71 collection sites in the northern hemisphere and 1090 patients from 12 collection sites in the southern hemisphere. Patient data variables were obtained from records or interviews. Solar insolation data were obtained from The National Aeronautics and Space Administration (NASA) Power database for each onset location, and the ratio of the mean monthly minimum/mean monthly maximum solar insolation was calculated. Typically, the ratio is largest near the equator (little yearly change in solar insolation) and smallest near the poles (large yearly change in solar insolation). Results A significant relationship was found between a family history of any mood disorder, the ratio of the mean monthly minimum/mean monthly maximum solar insolation, and gender. The odds of a family history of mood disorder increased as patient location nears the poles and decreased near the equator. Female gender also increased the odds of having a family history of a mood disorder. Conclusions This study highlighted the association between family history, solar insolation, and gender in international patients with bipolar I disorder. Given the profound effects of sunlight on human health, the family of patients with bipolar disorder who live in the same location with the same solar insolation, and especially females, may be at increased risk for a mood disorder.
Left Atrial Thrombus Occurring in Sinus Rhythm: Role of Variants of the Atrial Septum
Padang, Ratnasari , Sinak, Lawrence J., Krishnan, Subramaniam C.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 25, 2025 | Volume: 18 | Issue: 10 | Pages: No page available

10.1161/circep.125.014050 | PMID 41118447 Get It

ACR–ABS–ACNM–ARS–SIR–SNMMI Practice Parameter for Radioembolization of Liver Malignancies
Johnson, Thor, Spieler, Benjamin , Toskich, Beau , Wang, David S. , Russo, Suzanne , Sharma, Navesh , Wright, Chadwick , Farsad, Khashayar , Muzahir, Saima , Chundury, Anupama , Subramaniam, Rathan M. , Caplin, Drew M. , Schechter, Naomi R., Toskich, Beau B. , Hathout, Lara , Russo, Suzanne , Kim, Charles , Kappadath, Srinivas Cheenu , Parent, Ephraim E. , Sio, Terence T. , Mercier, Gustavo , Ghesani, Munir V. , Small, William

Mayo Clinic

American Journal of Clinical Oncology | September 3, 2025 | Volume: 49 | Issue: 1 | Pages: 10-24

10.1097/coc.0000000000001234 | PMID 40899409 Get It

Objectives: The practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), the American College of Nuclear Medicine (ACNM), the American Radium Society (ARS), the Society of Interventional Radiology (SIR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This document summarizes current evidence-based guidelines for the administration of Yttrium radioembolic therapy to the liver, including training requirements, evidence-based guidelines for administration, and safe practice for administration. Methods: This practice parameter was revised according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Interventional and Cardiovascular Radiology of the ACR Commission on Interventional and Cardiovascular, Committee on Practice Parameters and Technical Standards—Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters—Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ABS, the ACNM, the ARS, the SIR, and the SNMMI. Results: This review seeks not to be a comprehensive discussion of radiotherapy to the liver, but rather, seeks to provide a parameter for safe and effective therapy. We discuss the qualifications of physicians involved in this therapy, basic indications, contraindications, procedural work-up, safe-handling, and regulatory requirement for the administration of selective internal radiation therapy to patients that are likely to benefit. The goal of this document is not to define which patients are best treated by these therapies, as this is best determined for individual patients after multidisciplinary review. A consistent and evidence-based approach to therapy, however, would benefit all patients who are offered this therapy. This document seeks to provide a framework for current best practices for the administration of the 2 currently available radioembolization devices. Conclusions: As Yttrium-90 radiotherapy to the liver occupies a growing role in the treatment of primary and metastatic liver cancer, this review seeks to assist clinicians of all involved specialties to optimize the efficacy and safety of these procedures.
Topical hemostatic agents in endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review
Gralnek, Ian M. , Alkandari, Asma , Alali, Ali , Haidry, Rehan , Papaefthymiou, Apostolis , Radaelli, Franco , Subramaniam, Sharmila , Fuccio, Lorenzo , Bhandari, Pradeep , Alali, Ali , Papaefthymiou, Apostolis , Radaelli, Franco , Subramaniam, Sharmila , Fuccio, Lorenzo

Mayo Clinic

Endoscopy | July 30, 2025 | Volume: 57 | Issue: 10 | Pages: 1150-1173

10.1055/a-2646-7556 | PMID 40738122 Get It

Abstract Gastrointestinal (GI) endoscopy has evolved from a diagnostic tool into a therapeutic modality, leading to a higher incidence of bleeding complications during and after procedures. To address this issue, various hemostatic agents have been developed, including injectable, mechanical, thermal, and topical products. Topical hemostatic agents, available in powder or gel forms, can be used as standalone treatments or as adjuncts to traditional hemostatic therapies to control or prevent bleeding. This Technical and Technology Review examines the commercially available topical hemostatic agents used in endoscopy, specifically Purastat, TC-325 Hemospray, EndoClot PHS, Nexpowder, Ankaferd Blood Stopper, and CG GEL. A systematic literature review was conducted up to January 2025, focusing on randomized controlled trials (RCTs), meta-analyses, and observational studies. Each product was assessed for its composition, mechanism of action, regulatory status, mode of use, efficacy, safety, and financial considerations. Purastat showed 94% efficacy in acute GI bleeding, reducing delayed bleeding to 4.3% in endoscopic submucosal dissection (ESD) and endoscopic mucosal resection cases, with significantly lower thermal device usage. TC-325 Hemospray achieved 85%–98.5% primary hemostasis in upper and lower GI bleeding, with pooled hemostasis rates of 93.1% and rebleeding rates of 8.9%. It was also effective in malignancy-related bleeding, with hemostasis success up to 100%. EndoClot PHS demonstrated 76%–100% hemostasis efficacy, comparable with TC-325, with rebleeding rates of 24%–25%. It showed prophylactic potential post-ESD, with rebleeding rates of 7.3%–9.1%. Nexpowder achieved 94% hemostasis in refractory upper GI bleeds and reduced rebleeding in lower GI bleeds to 5.5% at 28 days. Ankaferd Blood Stopper demonstrated 73%–100% hemostasis across various GI bleeding sources, including peptic ulcers and malignancies, though further data on rebleeding are needed. Topical hemostatic agents offer effective options for managing GI bleeding. Products like Purastat, TC-325 Hemospray, EndoClot PHS, Nexpowder, Ankaferd Blood Stopper, and CG GEL have shown promising results in achieving hemostasis; however, further RCTs and cost-effectiveness analyses are needed to better establish their roles in endoscopic practice.
A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19
Kashem, Mohammed A. , Loor, Gabriel , Emtiazjoo, Amir , Hartwig, Matthew G. , Raemdonck, Dirk Van , Calvelli, Hannah , Pena, A. Leon, Salan‐Gomez, Marcelo , Warnick, Michael, Villavicencio, Mauricio A. , Ius, F. , Salman, J. , Chandrashekaran, Satish, Machuca, Tiago , Sánchez, Pablo G. , Neyrinck, Arne , Huddleston, Stephen J. , Ceulemans, Laurens J. , D'Silva, Ethan , Ramamurthy, Uma , Shaffer, Andrew , Langer, Nathaniel B. , Toyoda, Yoshiya , Van Raemdonck, Dirk , Villavicencio, Mauricio, Salman, Jawad , Sanchez, Pablo G , Huddleston, Stephen , Osho, Asishana , Ceulemans, Laurens J , Zhao, Huaqing , Ghadimi, Kamrouz , Subramaniam, Kathirvel , Osho, Asishana A.

Mayo Clinic

Clinical Transplantation | September 24, 2024 | Volume: 38 | Issue: 9 | Pages: No page available

10.1111/ctr.15462 | PMID 39315691 Get It

ABSTRACTIntroductionLung transplantation has become increasingly utilized in patients with COVID‐19. While several single‐center and UNOS database studies have been published on lung transplants (LTs) for end‐stage lung disease (ESLD) from Coronavirus disease 2019 (COVID‐19), there is a lack of multi‐center and international data.MethodsThis is a multicenter analysis from 11 high‐volume lung transplant centers in the United States and Europe. Data were collected through the Multi‐Institutional ECLS Registry and stratified by ESLD due to COVID‐19 versus other etiologies. Demographics and clinical variables were compared using Chi‐square test and Fisher's exact test. Survival was assessed by Kaplan‐Meier curves and compared by log‐rank test with propensity score matching.ResultsOf 1606 lung transplant recipients, 46 (2.9%) were transplanted for ESLD from COVID‐19 compared to 1560 (97.1%) without a history of COVID‐19. Among COVID‐19 patients, 30 (65.2%) had COVID‐19‐associated ARDS and 16 (34.8%) had post‐COVID‐19 fibrosis. COVID‐19 patients had higher lung allocation scores (78.0 vs. 44.4, p < 0.0001), had severely limited functional status (37.0% vs. 2.9%, p < 0.0001), had higher preoperative ECMO usage (65.2% vs. 5.4%, p < 0.0001), and spent less time on the waitlist (32 vs. 137 days, p < 0.0001). A 30‐day survival was comparable between COVID‐19 and non‐COVID‐19 patients before (100% vs. 98.7%, p = 0.39) and after propensity matching (p = 0.15).ConclusionsPatients who received LTs due to COVID‐19 had short‐term survival comparable to that of patients without COVID‐19. Our findings support the idea that lung transplantation should be considered for select patients with ESLD due to COVID‐19.
Gender Difference in Plasma and Urinary Oxalate Levels in a Mouse Model for Primary Hyperoxaluria Type 1
Subramaniam, Marina, Arukha, Ananta Prasad, Shaikh, Soorih, Subahi, Mohamed, Nayir, Mohammed H. El, Regalia, Destiny, Dawood, Dawood Al, Dumenya, Mmanuel A., Roy‐Chowdhury, Jayanta , Hassan, Hatim , Baranwal, Gaurav

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 490-490

10.1681/asn.20233411s1490c Get It

Abstract 5685: TGF-beta Signaling and Kruppel-like Factor 10 Regulate Bone Marrow-derived EPC Differentiation, Function, and Neovascularization
Wara, Akm Khyrul , Foo, ShiYin, Cao, Zhuoxiao, Subramaniam, Malayannan , Spelsberg, Thomas C, Icli, Basak , Cao, Zhuoxiao, Esen, Fehim , Spelsberg, Thomas C, Rosenzweig, Anthony , Feinberg, Mark W.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 120 | Issue: suppl_18 | Pages: No page available

10.1161/circ.120.suppl_18.s1140-a Get It

Background: Endothelial progenitor cells (EPCs) may originate from the bone marrow and are capable of contributing to cardiovascular regeneration. However, the identities of these bone marrow cells and the signaling pathways that regulate their differentiation into functional EPCs remain poorly understood. Hematopoiesis consists of a cascade by which hematopoietic stem cells (HSCs) give rise to either a common myeloid progenitor (CMPs) or common lymphoid progenitor (CLPs). The CMP cells can give rise to either granulocyte-monocyte progenitors (GMPs) or megakaryocyte-erythrocyte progenitors (MEPs). Methods and Results: Herein, we identify that CMPs and GMPs preferentially differentiate into CD34+KDR+ EPCs as measured by FACS, uptake of DiIacLDL and U.lex Lectin, matrigel studies, and endothelial markers. Co-culture studies in matrigel demonstrate increased network formation and incorporation when HUVECs were co-incubated with CMPs and GMPs only. Treatment of CMPs or GMPs with IFN-g blocked EPC differentiation, whereas treatment with TGF-b1 potently induced EPC differentiation. Conversely, EPC formation was markedly impaired using blocking antibodies or TGF-b1 deficient CMPs or GMPs, whereas IFN-g deficient mice have increased EPC differentiation. Functionally, EPCs derived from CMPs and GMPs more potently adhered to fibronectin-coated plates, migrated faster in transwell Boyden chambers, and released VEGF nearly ~2 to 2.5-fold higher than EPCs from MEPs and HSCs. Finally, we identified that a TGF-b1-responsive Kruppel-like transcription factor, KLF10, as robustly expressed ~60-fold in EPCs derived from CMPs and GMPs, compared to hematopoietic progenitors lacking EPC markers. Consistently, KLF10−/− mice have marked defects in EPC differentiation (−23.6% vs. WT, P<0.002), TGF-b1 responsiveness (completedly abolished), and impaired blood flow recovery in response to hindlimb ischemia (−23.8% vs. WT, P<0.008), an effect associated with reduced levels of circulating EPCs (−28.2% vs. WT, P<0.05). Conclusion: Among bone marrow progenitors, a hierarchy exists for EPC differentiation. Targeting KLF10 may alter EPC differentiation from bone marrow-derived CMPs and GMPs and influence cardiovascular repair.